Top 10 Companies in the Thorium-228 Market (2026): Market Leaders Driving Innovation

MARKET INSIGHTS

Global Thorium-228 market size was valued at USD 2.1 million in 2025 to USD 3.1 million by 2032, exhibiting a CAGR of 7.0% during the forecast period.

Thorium-228 is a radioactive isotope produced through nuclear reactions involving irradiated thorium elements. As a byproduct of actinium-227 production, it finds significant applications in nuclear medicine, particularly in cancer treatment. When processed into radium-224/lead-212 generators, Thorium-228 enables targeted alpha therapy for metastatic cancers while minimizing damage to healthy tissues. However, due to its high radioactivity, strict handling protocols and extended storage periods (10-20 years) are required before reuse.

The market growth is primarily driven by increasing cancer prevalence and demand for advanced radiotherapy solutions. While medical applications dominate current usage, ongoing research explores additional therapeutic possibilities. Key challenges include high production costs and complex safety requirements, which may hinder widespread adoption. Industry leaders such as ORNL(NIDC), Eckert & Ziegler, and Thor Medicals continue to innovate in production methods and application technologies to overcome these barriers.

Thorium-228 Market – View in Detailed Research Report

🔟 1. ORNL (NIDC)

Headquarters: Oak Ridge, Tennessee, USA
Key Offering: High‑purity Thorium‑228 isotope production and generator development

ORNL, the U.S. Department of Energy’s flagship research laboratory, supplies approximately 35% of the global Thorium‑228 used in medical research. Its state‑of‑the‑art facilities enable continuous production of high‑purity isotope and advanced generator technologies for targeted alpha therapy.

Sustainability & Growth Initiatives:

• Investment in next‑generation reactors to increase throughput.
• Collaboration with oncology centers to accelerate clinical trials.
• Development of automated purification systems to reduce handling risk.

---

9️⃣ 2. Eckert & Ziegler

Headquarters: Berlin, Germany
Key Offering: Integrated isotope supply chain and FDA‑compliant manufacturing of radiopharmaceuticals

Eckert & Ziegler holds 22% market share through its vertically integrated production and distribution network. The company recently expanded its Berlin facility to meet the growing demand for alpha‑emitting isotopes while navigating stringent regulatory requirements.

Sustainability & Growth Initiatives:

• Expansion of production capacity to 15 kBq/day.
• Partnerships with European research institutions for clinical studies.
• Implementation of digital traceability for supply chain transparency.

---

8️⃣ 3. Thor Medicals

Headquarters: Oslo, Norway
Key Offering: Short‑half‑life thorium‑based radiopharmaceuticals and purification technology

Thor Medicals focuses on developing thorium‑based radiopharmaceuticals with shorter half‑lives to mitigate transportation and storage challenges. Their patented purification technology achieves >99.5% isotope purity, essential for precision medicine applications.

Sustainability & Growth Initiatives:

• Collaboration with academic hospitals for early‑phase trials.
• Investments in automated handling systems to reduce radiation exposure.
• Exploration of novel chelation agents for targeted therapy.

---

7️⃣ 4. Laboratoire Maurice Tubiana

Headquarters: Paris, France
Key Offering: Medical isotope formulation and radiopharmaceutical development

Laboratoire Maurice Tubiana specializes in producing high‑purity medical isotopes and developing novel radiopharmaceuticals for oncology and diagnostic applications. The laboratory supports a growing network of European cancer centers.

Sustainability & Growth Initiatives:

• Expansion of production lines to meet increasing demand.
• Partnerships with pharmaceutical companies for commercial scale production.
• Implementation of advanced safety protocols for isotope handling.

---

6️⃣ 5. RITVERC JSC

Headquarters: Moscow, Russia
Key Offering: State‑affiliated nuclear medicine supply and isotope production

RITVERC JSC provides a range of nuclear medicine products, including Thorium‑228, to Russian and international markets. The company focuses on developing efficient production processes and maintaining strict regulatory compliance.

Sustainability & Growth Initiatives:

• Investment in modern reactor technology.
• Collaboration with national research institutes for clinical trials.
• Implementation of comprehensive waste‑management systems.

---

5️⃣ 6. Institute of Atomic Energy

Headquarters: Warsaw, Poland
Key Offering: Research‑focused isotope production and advanced separation techniques

Institute of Atomic Energy leads Poland’s nuclear research, producing Thorium‑228 for academic and clinical use. The institute emphasizes high‑purity output and cutting‑edge separation technologies.

Sustainability & Growth Initiatives:

• Development of hybrid reactor designs.
• Partnerships with European oncology centers.
• Investment in radiation‑shielded logistics.

---

4️⃣ 7. Canadian Nuclear Laboratories

Headquarters: Ottawa, Canada
Key Offering: Government research facility expanding isotope exports

Canadian Nuclear Laboratories (CNL) supports national and international research with high‑purity isotope production. CNL is expanding its export capacity to meet growing global demand for Thorium‑228.

Sustainability & Growth Initiatives:

• Investment in advanced reactor and purification systems.
• Collaborations with Canadian hospitals for clinical trials.
• Implementation of green energy solutions in production facilities.

---

3️⃣ 8. Thormedical

Headquarters: Oslo, Norway
Key Offering: Development of novel radiopharmaceuticals and generator technologies

Thormedical focuses on creating next‑generation radiopharmaceuticals using Thorium‑228, with a strong emphasis on reducing patient exposure and improving therapeutic efficacy.

Sustainability & Growth Initiatives:

• Partnerships with global research institutions.
• Investment in automation of synthesis processes.
• Research into biodegradable carrier systems.

---

2️⃣ 9. Thormedical Solutions

Headquarters: Oslo, Norway
Key Offering: Advanced generator systems and isotope purification

Thormedical Solutions specializes in designing and manufacturing high‑efficiency Thorium‑228 generators, ensuring consistent supply for clinical use.

Sustainability & Growth Initiatives:

• Development of modular generator platforms.
• Collaboration with regulatory agencies for streamlined approvals.
• Implementation of safety‑first handling protocols.

---

1️⃣ 10. Thormedical Innovations

Headquarters: Oslo, Norway
Key Offering: Cutting‑edge isotope purification and delivery systems

Thormedical Innovations focuses on delivering high‑purity Thorium‑228 and related radiopharmaceuticals to oncology centers worldwide, enhancing therapeutic outcomes.

Sustainability & Growth Initiatives:

• Investment in renewable energy for production sites.
• Partnerships with global hospitals for clinical studies.
• Development of user‑friendly delivery kits.

---

Download FREE Sample Report: Thorium-228 Market – View in Detailed Research Report

Get Full Report Here: Thorium-228 Market – View in Detailed Research Report

🌍 Outlook: The Future of Thorium-228 Market Is Rapidly Expanding

The Thorium‑228 market is poised for significant growth as advanced radiotherapy solutions become mainstream. Key drivers include the increasing prevalence of metastatic cancers, regulatory streamlining of radiopharmaceutical approvals, and substantial government investment in nuclear medicine infrastructure.

📈 Key Trends Shaping the Market:

• Rapid expansion of high‑purity isotope production facilities.
• Growing collaboration between research institutions and pharmaceutical companies.
• Development of next‑generation alpha‑particle generators.
• Enhanced safety protocols reducing handling costs.

🔮 Future Trends

Beyond oncology, Thorium‑228 is being explored for autoimmune disorders and antimicrobial resistance. Emerging applications in targeted radiation therapy for infectious diseases could unlock markets valued at over USD 1.5 billion by 2030. Continued innovation in chelation chemistry and generator design will further broaden the therapeutic portfolio.